Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Jul 3;36(13):1806-1808.
doi: 10.15252/embj.201796999. Epub 2017 May 15.

c-MYC mRNA tail tale about glutamine control of transcription

Affiliations
Comment

c-MYC mRNA tail tale about glutamine control of transcription

Chi V Dang. EMBO J. .

Abstract

Dejure et al (2017) demonstrates an intriguing link between glutamine, c‐MYC protein levels, and c‐MYC‐dependent transcription. Glutamine‐dependent c‐MYC protein level, which is sensed through the c‐MYC mRNA 3′‐UTR, determines global transcriptional response to glutamine deprivation in HCT116 colon cancer cells. These findings add another layer of complexity to c‐MYC's role as a nexus in metabolic regulation.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Glutamine‐dependent MYC‐mediated transcription
The diagram illustrates the finding by Dejure et al (2017) that glutamine contributes to adenosine synthesis, which in turn promotes c‐MYC mRNA translation via the 3′‐UTR. However, as depicted, whether adenosine signals directly or indirectly to the 3′‐UTR via a protein, such as HuR remains to be established. HuR has been documented to affect c‐MYC mRNA level and translation. Further, whether adenosine plays a role in signaling via an adenosine receptor or is involved in RNA editing (through adenosine deaminase acting on RNA or ADAR) or synthesis requires additional studies. Although glutamine does not seem to affect c‐MYC protein stability in HCT116 cells, it has been shown to affect O‐linked glycosylation and stability of c‐MYC protein. The diagram also illustrates that c‐MYC levels are regulated by a number of factors that affect transcription through RNA polymerase II (Pol II) pause‐release.

Comment on

References

    1. Altman BJ, Stine ZE, Dang CV (2016) From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer 16: 619–634 - PMC - PubMed
    1. Dang CV (2017) A time for MYC: metabolism and therapy. Cold Spring Harb Symp Quant Biol 81: 79–83 - PubMed
    1. Davidson SM, Papagiannakopoulos T, Olenchock BA, Heyman JE, Keibler MA, Luengo A, Bauer MR, Jha AK, O'Brien JP, Pierce KA, Gui DY, Sullivan LB, Wasylenko TM, Subbaraj L, Chin CR, Stephanopolous G, Mott BT, Jacks T, Clish CB, Vander Heiden MG (2016) Environment impacts the metabolic dependencies of ras‐driven non‐small cell lung cancer. Cell Metab 23: 517–528 - PMC - PubMed
    1. Dejure FR, Royla N, Herold S, Kalb J, Walz S, Ade CP, Mastrobuoni G, Vanselow JT, Schlosser A, Wolf E, Kempa S, Eilers M (2017) The MYC mRNA 3’‐UTR couples RNA polymerase II function to glutamine and ribonucleotide levels. EMBO J 36: 1854–1868 - PMC - PubMed
    1. Gross MI, Demo SD, Dennison JB, Chen L, Chernov‐Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, Mackinnon AL, Parlati F, Rodriguez ML, Shwonek PJ, Sjogren EB, Stanton TF, Wang T, Yang J, Zhao F, Bennett MK (2014) Antitumor activity of the glutaminase inhibitor CB‐839 in triple‐negative breast cancer. Mol Cancer Ther 13: 890–901 - PubMed

LinkOut - more resources